The AMBASSADOR trial revealed improvement in disease-free survival with adjuvant pembrolizumab in patients with high-risk muscle-invasive urothelial carcinoma compared to observation.1 In this Viewpoint, we discuss the clinical implications of these findings in the context of prior data from the CheckMate-274 and the recently published NIAGARA trial, envisioning the path forward for perioperative immunotherapy.
Med (New York, N.Y.). 2024 Dec 13 [Epub]
Kriti Mittal, Monika Joshi
University of Massachusetts Medical Center, Worcester, MA, USA., Penn State Cancer Institute, Hershey, PA, USA. Electronic address: .